Ursodeoxycholic acid, also known as ursodiol, is a bile acid produced by the liver that is often used for medical purposes to dissolve and flush cholesterol gallstones. It acts on the liver to help dissolve cholesterol gallstones and improve liver function by mitigating the toxicity of other bile acids. The global Ursodeoxycholic Acid Market is primarily driven by the increasing use of ursodeoxycholic acid in treatment of liver diseases, specifically primary biliary cholangitis. Ursodeoxycholic acid has emerged as a frequently used treatment option for alleviating symptoms and slowing the progression of primary biliary cholangitis.

The Global Ursodeoxycholic Acid Market is estimated to be valued at US$ 737.8 Mn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Ursodeoxycholic Acid are Philips, GE Healthcare, Medtronic, Siemens Healthineers, Stryker, Abbott, Boston Scientific, Johnson & Johnson, Canon Medical Systems, Baxter. Being one of the few available treatment options for primary biliary cholangitis, the demand for ursodeoxycholic acid is growing remarkably for management of the disease. Moreover, increasing awareness about liver diseases and expanding research on clinical applications of ursodeoxycholic acid are fueling the global market.

 

The growing burden of liver diseases worldwide is propelling research and development activities in ursodeoxycholic acid. Major players are investing in clinical trials to explore new therapeutic applications of ursodeoxycholic acid in treatment of other chronic liver conditions. Furthermore, manufacturing and supply chain expansion strategies by key players are helping increase the global accessibility of ursodeoxycholic acid.

Market drivers

Increasing prevalence of primary biliary cholangitis is a major factor accelerating the demand for ursodeoxycholic acid. As per scientific studies, the global prevalence of primary biliary cholangitis ranges between 40-400 cases per million. The disease majorly affects women and is more common in developed nations. Moreover, growing geriatric population who are more susceptible to developing liver diseases also contributes to the increasing for Ursodeoxycholic Acid Market Demand based treatment regimens.

Fastest growing region for Ursodeoxycholic Acid Market

Asia Pacific presents immense opportunities and is emerging as the fastest growing regional market for ursodeoxycholic acid. Improvements in patient access to sophisticated tertiary care, expansion of healthcare insurance coverage, rising per capita incomes and greater preference for patented pharmaceuticals are some key factors driving robust market growth. Countries like China, India, Indonesia, Thailand and South Korea are witnessing steep rise in the incidence of diseases indicating use of ursodeoxycholic acid. The presence of leading global medical device manufacturers establishing manufacturing facilities in the region ensures sufficient product availability. Moreover, strategic collaborations of international players with regional generic drug makers will help cater to the large population base. The various government initiatives encouraging local production are promoting competition and reducing treatment costs which in turn will augment the adoption and revenue generation from ursodeoxycholic acid market in Asia Pacific.

Explore more information on this topic, Please visit -

https://www.trendingwebwire.com/ursodeoxycholic-acid-market-outlook-and-growth-analysis/